BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a ...

Boston Scientific announced the acquisition in January, but the review dragged on after the Federal Trade Commission ...

Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).

Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of Axonics Inc. after entering into a purchase agreement in January.

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Boston Scientific Corp. last week announced that it has closed on its acquisition of Irvine-based medical device maker ...

Boston Scientific (BSX) announced the close of its acquisition of Axonics (AXNX). The purchase price of $71 cash per share represents an ...

Boston Scientific (BSX) announced the close of its acquisition of Axonics (AXNX). The purchase price of $71 cash per share represents an equity value of $3.7B and an enterprise value of $3.3B.

MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the close of its Acquisition of Axonics, Inc. (Nasdaq: AXNX ), a medical technology ...

"Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence," said Meghan Scanlon, senior vice president ...